Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 4 de 4
Filter
Add more filters










Database
Language
Publication year range
1.
Sci Rep ; 7(1): 7348, 2017 08 04.
Article in English | MEDLINE | ID: mdl-28779160

ABSTRACT

c-Jun N-terminal kinase (JNK) is a member of the mitogen-activated protein kinase family and controls various physiological processes including apoptosis. A specific upstream activator of JNKs is the mitogen-activated protein kinase kinase 7 (MKK7). It has been reported that MKK7-JNK signaling plays an important regulatory role in neural development, however, post-developmental functions in the nervous system have not been elucidated. In this study, we generated neuron-specific Mkk7 knockout mice (MKK7 cKO), which impaired constitutive activation of JNK in the nervous system. MKK7 cKO mice displayed impaired circadian behavioral rhythms and decreased locomotor activity. MKK7 cKO mice at 8 months showed motor dysfunctions such as weakness of hind-limb and gait abnormality in an age-dependent manner. Axonal degeneration in the spinal cord and muscle atrophy were also observed, along with accumulation of the axonal transport proteins JNK-interacting protein 1 and amyloid beta precursor protein in the brains and spinal cords of MKK7 cKO mice. Thus, the MKK7-JNK signaling pathway plays important roles in regulating circadian rhythms and neuronal maintenance in the adult nervous system.


Subject(s)
MAP Kinase Kinase 7/metabolism , Motor Disorders/etiology , Motor Disorders/metabolism , Neurons/metabolism , Stress, Physiological , Age Factors , Animals , Brain/diagnostic imaging , Brain/metabolism , Brain/physiopathology , Circadian Rhythm/genetics , Disease Models, Animal , Disease Progression , Gene Deletion , JNK Mitogen-Activated Protein Kinases/metabolism , MAP Kinase Kinase 7/genetics , MAP Kinase Signaling System , Male , Mice , Mice, Transgenic , Motor Activity , Motor Disorders/diagnosis , Organ Specificity , Rats
2.
Sci Rep ; 6: 37697, 2016 11 24.
Article in English | MEDLINE | ID: mdl-27883036

ABSTRACT

The primitive streak in peri-implantation embryos forms the mesoderm and endoderm and controls cell differentiation. The metabolic cues regulating primitive streak formation remain largely unknown. Here we utilised a mouse embryonic stem (ES) cell differentiation system and a library of well-characterised drugs to identify these metabolic factors. We found that statins, which inhibit the mevalonate metabolic pathway, suppressed primitive streak formation in vitro and in vivo. Using metabolomics and pharmacologic approaches we identified the downstream signalling pathway of mevalonate and revealed that primitive streak formation requires protein farnesylation but not cholesterol synthesis. A tagging-via-substrate approach revealed that nuclear lamin B1 and small G proteins were farnesylated in embryoid bodies and important for primitive streak gene expression. In conclusion, protein farnesylation driven by the mevalonate pathway is a metabolic cue essential for primitive streak formation.


Subject(s)
Metabolic Networks and Pathways , Mevalonic Acid/metabolism , Primitive Streak/embryology , Primitive Streak/metabolism , Protein Prenylation , Animals , Cell Differentiation , Down-Regulation/genetics , Embryoid Bodies , Gene Expression Regulation, Developmental , Metabolome , Metabolomics , Mice, Inbred ICR , Myocytes, Cardiac/cytology , Myocytes, Cardiac/metabolism , Neurogenesis , Oligonucleotide Array Sequence Analysis , Organogenesis , Zebrafish
3.
PLoS One ; 10(12): e0145286, 2015.
Article in English | MEDLINE | ID: mdl-26682887

ABSTRACT

Mammalian fetal development is easily disrupted by exogenous agents, making it essential to test new drug candidates for embryotoxicity and teratogenicity. To standardize the testing of drugs that might be used to treat pregnant women, the U.S. Food and Drug Administration (FDA) formulated special grade categories, labeled A, B, C, D and X, that define the level of risk associated with the use of a specific drug during pregnancy. Drugs in categories (Cat.) D and X are those with embryotoxic and/or teratogenic effects on humans and animals. However, which stages of pregnancy are affected by these agents and their molecular mechanisms are unknown. We describe here an embryonic stem cell test (EST) that classifies FDA pregnancy Cat.D and Cat.X drugs into 4 classes based on their differing effects on primitive streak formation. We show that ~84% of Cat.D and Cat.X drugs target this period of embryogenesis. Our results demonstrate that our modified EST can identify how a drug affects early embryogenesis, when it acts, and its molecular mechanism. Our test may thus be a useful addition to the drug safety testing armamentarium.


Subject(s)
Benzodiazepines/toxicity , Mouse Embryonic Stem Cells/drug effects , Teratogens/toxicity , Tretinoin/toxicity , Animals , Biomarkers/metabolism , Cell Differentiation/drug effects , Embryoid Bodies/drug effects , Embryoid Bodies/physiology , Embryonic Development/drug effects , Gene Expression/drug effects , Mice , Mouse Embryonic Stem Cells/physiology , Teratogenesis , Teratogens/classification , Toxicity Tests
4.
Biochem Biophys Res Commun ; 435(3): 447-53, 2013 Jun 07.
Article in English | MEDLINE | ID: mdl-23665324

ABSTRACT

Muscarinic acetylcholine receptors (mAchRs) are critical components of the cholinergic system, which is the key regulator of both the central and peripheral nervous systems in mammals. Interestingly, several components of the cholinergic system, including mAchRs and choline acetyltransferase (ChAT), have recently been found to be expressed in mouse embryonic stem (ES) cells and human placenta. These results raise the intriguing possibility that mAchRs play physiological roles in the regulation of early embryogenesis. Early embryogenesis can be mimicked in vitro using an ES cell-based culture system in which the cells form a primitive streak-like structure and efficiently develop into mesodermal progenitors. Here we report that chemical inhibitors specifically targeting mAchRs suppressed the expression of genes essential for primitive streak formation, including Wnt3, and thereby blocked mesodermal progenitor differentiation. Interestingly, mAchR inhibitors also reduced the expression of Cyp26a1, an enzyme involved in the catabolism of retinoic acid (RA). RA is an important regulator of Wnt3 signaling. Our study presents evidence indicating that mAchRs influence RA signaling necessary for the induction of the primitive streak. To our knowledge, this is the first report showing that mAchRs have important functions not only in adult mammals but also during early mammalian embryogenesis.


Subject(s)
Embryoid Bodies/metabolism , Primitive Streak/metabolism , Receptors, Muscarinic/physiology , Animals , Cell Differentiation/drug effects , Dicyclomine/pharmacology , Embryoid Bodies/cytology , Embryoid Bodies/drug effects , Gene Expression Regulation, Developmental/drug effects , Humans , Mice , Muscarinic Antagonists/pharmacology , Phenylpropionates/pharmacology , Primitive Streak/cytology , Primitive Streak/drug effects , Tretinoin/physiology
SELECTION OF CITATIONS
SEARCH DETAIL
...